Immune status in congenital infections by TORCH agents in pregnant Thais.

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Immune status in congenital infections by TORCH agents in pregnant Thais.

Asian Pac J Allergy Immunol. 1997 Jun;15(2):93-7. Unique Identifier : AIDSLINE MED/98004259
Taechowisan T; Sutthent R; Louisirirotchanakul S; Puthavathana P; Wasi C; Department of Biology, Faculty of Science, Silpakorn University,; Nakorn Pathom, Thailand.

Abstract: A cross-sectional, sero-epidemiological survey of the prevalence of antibodies to TORCH agents during various stages of gestation revealed an overall rate of 13-15 percent having antibodies to Toxoplasma gondii; 85-87 percent, to rubella ; 79-81 percent, to herpes simplex virus (HSV); 100 percent, to cytomegalovirus (CMV); 82-86 percent, to human herpes virus type 6 (HHV-6); 1-2 percent, to hepatitis C virus (HCV). None of human T lymphotropic virus type I (HTLV-I) antibody was detected, and a prevalence of hepatitis B surface antigen (HBsAg) was 6 percent. Although a tendency was noted towards an increase of antibody detection to each TORCH agent as gestation progressed, a statistically significant increase in antibodies titer and specific IgM antibody was found with regard to CMV. These results suggest an increase in CMV infection or reactivation during pregnancy whereas an increase in the other TORCH infections was not obvious.

Keywords: Adolescence Adult Antibodies, Protozoan/ANALYSIS Antibodies, Viral/ANALYSIS Cross-Sectional Studies Cytomegalovirus Infections/DIAGNOSIS/IMMUNOLOGY Female Hepatitis B Surface Antigens/ANALYSIS Hepatitis C/DIAGNOSIS/IMMUNOLOGY Herpes Simplex/DIAGNOSIS/IMMUNOLOGY Herpesviridae Infections/DIAGNOSIS/IMMUNOLOGY Human HTLV-I Infections/DIAGNOSIS/IMMUNOLOGY IgM/ANALYSIS/IMMUNOLOGY Pregnancy Pregnancy Complications, Infectious/*EPIDEMIOLOGY/PARASITOLOGY/ VIROLOGY Pregnancy Trimester, First/IMMUNOLOGY Pregnancy Trimester, Second/IMMUNOLOGY Pregnancy Trimester, Third/IMMUNOLOGY Prevalence Rubella/DIAGNOSIS/IMMUNOLOGY Seroepidemiologic Methods Thailand/EPIDEMIOLOGY Toxoplasmosis/DIAGNOSIS/*EPIDEMIOLOGY/IMMUNOLOGY Virus Diseases/DIAGNOSIS/*EPIDEMIOLOGY/IMMUNOLOGY JOURNAL ARTICLE
980228
M9820742

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .